Strong PhII data in triglyceride reduction attracts partners to Essentialis
This article was originally published in Scrip
Executive Summary
Essentialis Inc. is in discussions with partners and potential acquirers as its moves into Phase III clinical trials for diazoxide choline controlled-release tablets, or DCCR, a drug that may cause dramatic reductions in triglyceride levels for high-risk patients who already are taking cholesterol-lowering medications.
You may also be interested in...
Capina, Essentialis Merger To Create Rare Disease Firm
The combined company would advance a diazoxide choline controlled-release daily pill for treating patients with Prader-Willi syndrome through pivotal Phase II/III clinical trialing.
Early Promise Of NextCure’s Novel IO Candidate Continues To Fade
Lead immuno-oncology asset NC318 targeting Siglec-15 showed encouraging early activity in patients refractory to PD-1/L1 inhibitors, but now Phase II plans are scuttled in lung and ovarian cancers.
2020 VC Landscape: Reviewing The First Six Months
A steady flow of venture capital into the medical device industry continued in the first half of 2020 despite the novel coronavirus pandemic. While Biopharma companies secured more than $7.5bn in private financings between January and June.
Need a specific report? 1000+ reports available
Buy Reports